Phase 2 Chronic Kidney Disease Trial, Recruiting NCT06863194 Sponsor: Mansoura University Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 2 Chronic Kidney Disease Trial, Recruiting

NCT06863194
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any gender
  • People who have been diagnosed with Chronic Kidney Disease (CKD) at Stage 3 or Stage 4, confirmed by a specific kidney function test called eGFR
  • People whose condition is currently stable, with no recent hospital stays for sudden kidney problems or other serious illnesses
  • People who are not currently taking probiotic or prebiotic supplements
  • People who are willing to give their consent to participate and are able to follow the study requirements, including attending clinic visits and providing samples

Who may not be able to join:

  • People with CKD at Stage 1, 2, or 5, or who are currently on dialysis
  • People who are currently using probiotics or prebiotics, either as a supplement or as part of their treatment
  • People with a history of active cancer, or who are currently receiving chemotherapy
  • People with significant gut or digestive conditions, such as inflammatory bowel disease, irritable bowel syndrome, or those who have recently had gastrointestinal surgery
  • Women who are pregnant or breastfeeding
  • People who have an autoimmune disease, such as lupus or rheumatoid arthritis
  • People who have been taking long-term antibiotics or anti-inflammatory medications that could affect gut bacteria
  • People with severe behavioural or cognitive difficulties that may make it hard to follow the study requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 00201023771331

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Mansoura University
Registry
ClinicalTrials.gov
Start date
3 April 2025
Est. completion
3 October 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Change in Estimated Glomerular Filtration Rate (eGFR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov